Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction

被引:10
|
作者
Samson, Rohan [1 ]
Le Jemtel, Thierry H. [1 ]
机构
[1] Tulane Univ, Sch Med, John W Deming Dept Med, Cardiol Sect, 1430 Tulane Ave, New Orleans, LA 70112 USA
来源
关键词
coronary microvascular dysfunction; HFpEF; left ventricular remodeling; systemic inflammation; LEFT-VENTRICULAR HYPERTROPHY; CORONARY MICROVASCULAR DYSFUNCTION; INCIDENT CARDIOVASCULAR-DISEASE; C-REACTIVE PROTEIN; CONVERTING-ENZYME-INHIBITOR; LIPID-LOWERING TREATMENT; METABOLIC RISK-FACTORS; BODY-FAT DISTRIBUTION; ADIPOSE-TISSUE; BLOOD-PRESSURE;
D O I
10.1161/JAHA.121.021120
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The findings of randomized trials of neurohormonal modulation have been neutral in heart failure with preserved ejection fraction and consistently positive in heart failure with reduced ejection. Left ventricular remodeling promotes the development and progression of heart failure with preserved and reduced ejection fraction. However, different stimuli mediate left ventricular remodeling that is commonly concentric in heart failure with preserved ejection fraction and eccentric in heart failure with reduced ejection. The stimuli that promote concentric left ventricular remodeling may account for the neutral findings of neuhormonal modulation in heart failure with preserved ejection fraction. Low-grade systemic inflammation-induced microvascular endothelial dysfunction is currently the leading hypothesis behind the development and progression of heart failure with preserved ejection fraction. The hypothesis provided the rationale for several randomized controlled trials that have led to neutral findings. The trials and their limitations are reviewed.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Current Therapeutic Approach in Heart Failure with Preserved Ejection Fraction
    Nativi-Nicolau, Jose
    Ryan, John J.
    Fang, James C.
    HEART FAILURE CLINICS, 2014, 10 (03) : 525 - +
  • [2] The therapeutic potential of relaxin for heart failure with preserved ejection fraction
    Salama, G.
    Palma, J.
    Gabris-Weber, B.
    MacMahon, B.
    Kuhn, B.
    Dschietzig, T.
    Romero, G.
    EUROPEAN HEART JOURNAL, 2022, 43 : 777 - 777
  • [3] Inflammation as a therapeutic target in heart failure with preserved ejection fraction
    Peh, Zhen Hui
    Dihoum, Adel
    Hutton, Dana
    Arthur, J. Simon C.
    Rena, Graham
    Khan, Faisel
    Lang, Chim C. C.
    Mordi, Ify R.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [4] Heart failure with preserved ejection fraction
    Kessler, Kenneth M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (17): : 1829 - 1829
  • [5] Heart Failure with Preserved Ejection Fraction
    Meyer, Adam
    Kerrigan, Martin
    HOSPITAL MEDICINE CLINICS, 2015, 4 (03) : 283 - 296
  • [6] Heart Failure with Preserved Ejection Fraction
    Gladden, James D.
    Chaanine, Antoine H.
    Redfield, Margaret M.
    ANNUAL REVIEW OF MEDICINE, VOL 69, 2018, 69 : 65 - 79
  • [7] Heart Failure with Preserved Ejection Fraction
    Franssen, C.
    Paulus, W. J.
    NETHERLANDS JOURNAL OF CRITICAL CARE, 2012, 16 (04): : 125 - 132
  • [8] Heart failure with preserved ejection fraction
    Marzia Rigolli
    Gillian A Whalley
    Journal of Geriatric Cardiology, 2013, 10 (04) : 369 - 376
  • [9] Heart Failure with Preserved Ejection Fraction
    Culic, Viktor
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (09): : 896 - 896
  • [10] Heart failure with a preserved ejection fraction
    Warriner, D. R.
    Morris, P. D.
    Saraf, K.
    Al-Mohammad, A.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2013, 74 (02) : C26 - C30